Net revenue for 2025 was $4.3 million, a 35.8% decrease from $6.8 million in 2024. The company reported a net loss of $14.7 million for 2025, compared to a $53.4 million loss in 2024. Diagnostic services revenue was zero for 2025 as the company ceased these operations. The company deconsolidated its diagnostic subsidiaries (PDX) following their Chapter 11 bankruptcy filing on September 22, 2025. The company sold its Pharmaloz Manufacturing, Inc. (PMI) business in January 2025, resulting in a gain of $8.7 million. As of December 31, 2025, the company had $90,000 in cash and a working capital deficit of $49.9 million. The company is focusing on its genomics business (Nebula Genomics, DNA Complete) and biotechnology (BE-Smart test, Linebacker compounds).